

## EQA round: CSFB1/24 - Cerebrospinal Fluid Analysis

Deadline: 22.3.2024

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N <sub>tot</sub> = total number of the results		N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(333) Albumin</b>	[mg/L]				14							14	14	100	
<b>Sample A</b>		244	15	6,3	14		CVP	240	5,6	23%	184	296	14	14	100
(58) Beckman Coulter (AU)		241	1,4	0,58	5	0							5		
Other					9	0							9		
								1x 12, 2x 60, 1x 91, 3x 149, 1x 162, 1x 179							
<b>Sample B</b>		359	21	5,8	14		CVP	346	7,5	23%	266	426	14	14	100
(58) Beckman Coulter (AU)		351	6,6	1,9	5	0							5		
Other					9	0							9		
								1x 12, 2x 60, 1x 91, 3x 149, 1x 162, 1x 179							
<b>(330) Total protein</b>	[mg/L]				15								15	14	93
<b>Sample A</b>		401	28	6,9	15		CVP	405	5,9	27%	295	515	15	14	93
(58) Beckman Coulter (AU)		425	22	5,2	6	0							6		
Other					9	0							9		
								1x 1, 3x 60, 1x 75, 1x 77, 1x 85, 1x 178, 1x 998							
<b>Sample B</b>		915	42	4,6	15		CVP	904	12	27%	659	1150	15	14	93
(58) Beckman Coulter (AU)		897	48	5,4	6	0							6		
Other					9	0							9		
								1x 1, 3x 60, 1x 75, 1x 77, 1x 85, 1x 178, 1x 998							
<b>(331) Glucose</b>	[mmol/L]				15								15	15	100
<b>Sample A</b>		3,48	0,13	3,8	15		CVP	3,48	0,026	18%	2,85	4,11	15	15	100
(58) Beckman Coulter (AU)		3,47	0,19	5,3	7	0							7		
Other					8	0							8		
								3x 46, 3x 60, 1x 75, 1x 188							
<b>Sample B</b>		1,83	0,06	3,3	15		CVP	1,84	0,016	18%	1,5	2,18	15	15	100
(58) Beckman Coulter (AU)		1,82	0,096	5,3	7	0							7		
Other					8	0							8		
								3x 46, 3x 60, 1x 75, 1x 188							
<b>(335) IgA</b>	[mg/L]				4								4	4	100
<b>Sample A</b>					4	0							4	4	100
Other					4	0							4		
								1x 12, 1x 91, 2x 149							
<b>Sample B</b>					4	0							4	4	100
Other					4	0							4		
								1x 12, 1x 91, 2x 149							
<b>(334) IgG</b>	[mg/L]				10								10	10	100
<b>Sample A</b>					10	0							10	10	100
Other					10	0							10		
								1x 12, 1x 58, 1x 60, 2x 91, 4x 149, 1x 162							
<b>Sample B</b>					10	0							10	10	100
Other					10	0							10		
								1x 12, 1x 58, 1x 60, 2x 91, 4x 149, 1x 162							
<b>(336) IgM</b>	[mg/L]				5								5	5	100
<b>Sample A</b>					5	0							5	5	100
Other					5	0							5		
								1x 12, 1x 91, 3x 149							
<b>Sample B</b>					5	0							5	5	100
Other					5	0							5		
								1x 12, 1x 91, 3x 149							
<b>(338) Lactate</b>	[mmol/L]				14								14	14	100
<b>Sample A</b>		1,91	0,068	3,6	14		CVP	1,9	0,017	20%	1,52	2,28	14	14	100
(58) Beckman Coulter (AU)		1,91	0,052	2,7	5	0							5		
Other					9	0							9		
								1x 1, 4x 60, 1x 75, 1x 178, 2x 188							
<b>Sample B</b>		3,85	0,14	3,7	14		CVP	3,84	0,032	20%	3,07	4,61	14	14	100
(58) Beckman Coulter (AU)		3,91	0,13	3,4	5	0							5		
Other					9	0							9		
								1x 1, 4x 60, 1x 75, 1x 178, 2x 188							